{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:51:18Z","timestamp":1792619478435,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hoc.2023.12.005","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T15:49:19Z","timestamp":1703605759000},"page":"407-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?"],"prefix":"10.1016","volume":"38","author":[{"given":"Morie A.","family":"Gertz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Supplement","key":"10.1016\/j.hoc.2023.12.005_bib1","article-title":"Autologous stem cell transplantation for multiple myeloma in the novel agent era: Systematic review of Indian data and implications for resource constrained settings","volume":"19","author":"Singh","year":"2023","journal-title":"J\u00a0Cancer Res Ther"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.005_bib2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000437055","article-title":"Outcome in Multiple Myeloma Patients Eligible for Stem Cell Transplantation: A Single-Center Experience","volume":"89","author":"Lamm","year":"2015","journal-title":"Oncology"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.005_bib3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ajh.25797","article-title":"Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years","volume":"95","author":"Belotti","year":"2020","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.005_bib4","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/s41409-020-01159-9","article-title":"Autologous stem cell transplantation for multiple myeloma patients aged \u2265 75 treated with novel agents","volume":"56","author":"Vaxman","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.005_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/10428194.2022.2148214","article-title":"Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome","volume":"64","author":"Kumar","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.005_bib6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00277-023-05085-w","article-title":"Autologous stem cell transplantation in multiple myeloma patients with renal impairment","volume":"102","author":"Zhai","year":"2023","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.005_bib7","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41409-022-01657-y","article-title":"Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option","volume":"57","author":"Lazana","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.005_bib8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41409-023-01915-7","article-title":"Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMT","volume":"58","author":"Waszczuk-Gajda","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.005_bib9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/ejh.13961","article-title":"Validation of the role of corrected DLCO in predicting outcomes post autologous hematopoietic cell transplant for multiple myeloma","volume":"110","author":"Awada","year":"2023","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.005_bib10","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1111\/bjh.18753","article-title":"Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant","volume":"201","author":"Pasvolsky","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.005_bib11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clml.2021.07.030","article-title":"Multiple myeloma: risk adapted use of plerixafor for stem cell mobilization prior to autologous stem cell transplantation is effective and cost efficient","volume":"22","author":"Prakash","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.hoc.2023.12.005_bib12","first-page":"06","article-title":"Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials","volume":"06","author":"Chhabra","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.005_bib13","doi-asserted-by":"crossref","first-page":"340.e341","DOI":"10.1016\/j.jtct.2023.02.013","article-title":"Stem cell mobilization for multiple myeloma patients receiving daratumumab-based induction therapy: a real- world experience","volume":"29","author":"Thurlapati","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.005_bib14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-023-02273-z","article-title":"Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial","volume":"29","author":"Crees","year":"2023","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.005_bib15","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/s41409-019-0587-0","article-title":"High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma","volume":"54","author":"Gomez-Arteaga","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.005_bib16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ijrobp.2022.09.069","article-title":"Phase 1 study of the combination of escalated total marrow irradiation using helical tomotherapy and fixed high-dose melphalan (140\u00a0mg\/m2) followed by autologous stem cell transplantation at first relapse in multiple myeloma","volume":"115","author":"Cailleteau","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.005_bib17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/bjh.18716","article-title":"Clonal haematopoiesis of indeterminate potential predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma","volume":"201","author":"Li","year":"2023","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.005_bib18","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/bloodadvances.2022007838","article-title":"Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation","volume":"7","author":"Scordo","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.005_bib19","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/ctr.12421","article-title":"Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma","volume":"28","author":"Pandya","year":"2014","journal-title":"Clin Transplant"},{"issue":"13","key":"10.1016\/j.hoc.2023.12.005_bib20","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1080\/10428194.2021.1953011","article-title":"Health-related quality of life in transplant eligible multiple myeloma patients with or without early ASCT in the real-world setting","volume":"62","author":"Asrar","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.005_bib21","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S2352-3026(22)00350-7","volume":"10","author":"Yong","year":"2023","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.005_bib22","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1038\/s41409-021-01371-1","article-title":"Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma","volume":"56","author":"Lemieux","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2023.12.005_bib23","first-page":"05","article-title":"Outcomes after salvage autologous hematopoietic cell transplant for patients with relapsed\/refractory multiple myeloma: a single-institution experience","volume":"05","author":"Khan","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.hoc.2023.12.005_bib24","first-page":"20","article-title":"Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma","volume":"20","author":"Hashmi","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.005_bib25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbmt.2018.09.021","article-title":"High-dose chemotherapy with early autologous stem cell transplantation compared to standard dose chemotherapy or delayed transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.005_bib26","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.clml.2022.11.007","article-title":"Post salvage therapy autologous transplant for relapsed myeloma, ongoing relevance within modern treatment paradigms?","volume":"23","author":"Khan","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.005_bib27","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.005_bib28","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41375-020-0948-0","article-title":"Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide\/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE","volume":"35","author":"Goldschmidt","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.005_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.005_bib30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.005_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-022-00624-6","article-title":"Mass-fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702\/07LT)","volume":"12","author":"Dispenzieri","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.005_bib32","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4143\/crt.2022.952","article-title":"Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study","volume":"55","author":"Jung","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.hoc.2023.12.005_bib33","first-page":"30","article-title":"Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modelling","volume":"30","author":"Lawless","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2023.12.005_bib34","first-page":"23","article-title":"Allogeneic stem cell transplantation in patients with multiple myeloma-single center experience","volume":"23","author":"Kriz","year":"2023","journal-title":"Neoplasma"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.005_bib35","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.005_bib36","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/s12885-023-10907-1","article-title":"Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"23","author":"Lin","year":"2023","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.005_bib37","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00277-023-05177-7","article-title":"Clinical significance of high-dose chemotherapy with autologous stem cell transplantation in the era of novel agents in patients older than 65 years with multiple myeloma","volume":"102","author":"Sato","year":"2023","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.005_bib38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-023-00842-6","article-title":"Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients","volume":"13","author":"Pasvolsky","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.005_bib39","doi-asserted-by":"crossref","first-page":"260.e1-6","DOI":"10.1016\/j.jtct.2023.01.010","article-title":"Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience","volume":"29","author":"Pasvolsky","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.005_bib40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mayocp.2017.09.012","article-title":"Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma","volume":"93","author":"Gertz","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.005_bib41","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1038\/s41598-023-27465-y","article-title":"Incidence and risk factors of opportunistic infections after autologous stem cell transplantation: a nationwide, population-based cohort study in Korea","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.005_bib42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ajh.26596","article-title":"Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma","volume":"98","author":"D'Souza","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.005_bib43","doi-asserted-by":"crossref","first-page":"200.e1-8","DOI":"10.1016\/j.jtct.2022.11.030","article-title":"Fatigue in Hematopoietic Cell Transplantation Survivors: Correlates, Care Team Communication, and Patient-Identified Mitigation Strategies","volume":"29","author":"Ullrich","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"10.1016\/j.hoc.2023.12.005_bib44","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.2022017094","article-title":"High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma","volume":"141","author":"Samur","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.005_bib45","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","article-title":"Long-term outcomes after autologous stem cell transplantation for multiple myeloma","volume":"4","author":"Nishimura","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2023.12.005_bib46","doi-asserted-by":"crossref","first-page":"106710","DOI":"10.1016\/j.leukres.2021.106710","article-title":"Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma","volume":"110","author":"Tang","year":"2021","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.005_bib47","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.bbmt.2020.03.006","article-title":"Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients","volume":"26","author":"Blocka","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.005_bib48","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.13994","article-title":"Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial","volume":"173","author":"Mai","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.005_bib49","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.005_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-00390-3","article-title":"Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma","volume":"11","author":"Baertsch","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.005_bib51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","article-title":"Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Dytfeld","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.005_bib52","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/10428194.2022.2136946","article-title":"Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation","volume":"64","author":"Mikulski","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.005_bib53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/10428194.2022.2131410","article-title":"Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myeloma","volume":"64","author":"D'Angelo","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.005_bib54","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.005_bib55","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.005_bib56","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bjh.18600","article-title":"The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial","volume":"201","author":"Jenner","year":"2022","journal-title":"Br J Haematol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:18:09Z","timestamp":1760591889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823001727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0889858823001727"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}